The Food and Drug Administration has declined to approve InterMune Inc.’s experimental drug designed to treat an extremely rare lung disease and says it wants the company to conduct another clinical trial.
See the original post here:
FDA denies approval of InterMune lung drug
Popular Posts:
- AMCP Review of Health Care Reform Legislation (Part 1)
- Anadys hepatitis C drug meets key study goals
- Summary Box: Lilly halts Alzheimer’s drug
- Geron shares rise on stem cell study
- Geron shares rise on stem cell study